BOLT News and Press, Bolt Biotherapeutics Inc. From 05/11/23

2023-05-11 17:02:28 ET Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q1 GAAP EPS of -$0.45. Revenue of $1.83M (+125.9% Y/Y). For further details see: Bolt Biotherapeutics GAAP EPS of -$0.45, revenue of $1.83M

Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer Cash bal...

REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with clinical data from its compl...

2023-03-29 16:55:11 ET Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q4 GAAP EPS of -$0.53 beats by $0.05 . Revenue of $1.41M (+176.5% Y/Y) misses by $0.13M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.53 beats by $0.05, revenue ...

2023-03-29 16:28:37 ET Bolt Therapeutics ( NASDAQ: BOLT ) is up 7% in after-hours trading after reporting positive top-line results on BDC-1001 both alone and in combination with Opdivo (nivolumab) for multiple tumor types. The Immune-Stimulating Antibody Conjugate is ...

Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination ...

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumab Data support selection of a recommended Phase 2 dose and advancement into Phase 2 studies in breast, ...

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2023) - Bolt Metals Corp. (CSE: BOLT) (FSE: A2QEUB) (OTCQB: PCRCF) (" Bolt " or the " Company ") announces it has implemented a consolidation (the " Consolidation ") of its issued share capital on the basis of one (1) new common share for ev...

Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares. As a result, the outstanding shares ...

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annu...